References
Acevedo, V.D., Gangula, R.D., Freeman, K.W., et al. (2007). Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12, 559–571.
Affolter, M., Zeller, R., and Caussinus, E. (2009). Tissue remodelling through branching morphogenesis. Nat Rev Mol Cell Biol 10, 831–842.
Aguayo, S.M., Schuyler, W.E., Murtagh, J.J., Jr., and Roman, J. (1994). Regulation of lung branching morphogenesis by bombesin-like peptides and neutral endopeptidase. Am J Respir Cell Mol Biol 10, 635–642.
Awad, M.M., Katayama, R., McTigue, M., et al. (2013). Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368, 2395–2401.
Babij, C., Zhang, Y., Kurzeja, R.J., et al. (2011). STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res 71, 5818–5826.
Barbie, D.A., Tamayo, P., Boehm, J.S., et al. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112.
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297.
Bass, A.J., Watanabe, H., Mermel, C.H., et al. (2009). SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41, 1238–1242.
Belinsky, S.A., Nikula, K.J., Palmisano, W.A., et al. (1998). Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95, 11891–11896.
Bell, D.W., Lynch, T.J., Haserlat, S.M., et al. (2005). Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23, 8081–8092.
Bernstein, B.E., Birney, E., Dunham, I., et al. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74.
Bhattacharjee, A., Richards, W.G., Staunton, J., et al. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98, 13790–13795.
Bild, A.H., Yao, G., Chang, J.T., et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353–357.
Borczuk, A.C., Gorenstein, L., Walter, K.L., et al. (2003). Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 163, 1949–1960.
Borges, M., Linnoila, R.I., van de Velde, H.J., et al. (1997). An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 386, 852–855.
Brock, M.V., Hooker, C.M., Ota-Machida, E., et al. (2008). DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358, 1118–1128.
Burk, U., Schubert, J., Wellner, U., et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9, 582–589.
Cantley, L.C. (2002). The phosphoinositide 3-kinase pathway. Science 296, 1655–1657.
Carpten, J.D., Faber, A.L., Horn, C., et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439–444.
Chen, H., Biel, M.A., Borges, M.W., et al. (1997). Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions. Cell Growth Differ 8, 677–686.
Cheung, W.K., Zhao, M., Liu, Z., et al. (2013). Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis. Cancer Cell 23, 725–738.
Chin, L.J., Ratner, E., Leng, S., et al. (2008). A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68, 8535–8540.
Davies, H., Hunter, C., Smith, R., et al. (2005). Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65, 7591–7595.
Delmore, J.E., Issa, G.C., Lemieux, M.E., et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917.
Der, C.J., Krontiris, T.G., and Cooper, G.M. (1982). Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 79, 3637–3640.
Ding, L., Getz, G., Wheeler, D.A., et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075.
Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3, 11–22.
Dvorak, H.F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315, 1650–1659.
Engelman, J.A., Chen, L., Tan, X., et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14, 1351–1356.
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043.
Esquela-Kerscher, A., Trang, P., Wiggins, J.F., et al. (2008). The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7, 759–764.
Feinberg, A.P., and Tycko, B. (2004). The history of cancer epigenetics. Nat Rev Cancer 4, 143–153.
Feinberg, A.P., and Vogelstein, B. (1983). Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 111, 47–54.
Fire, A., Xu, S., Montgomery, M.K., et al. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811.
Forbes, S.A., Tang, G., Bindal, N., et al. (2010). COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38, D652–657.
Fraga, M.F., Ballestar, E., Villar-Garea, A., et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37, 391–400.
Fuchs, B.C., Fujii, T., Dorfman, J.D., et al. (2008). Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68, 2391–2399.
Garraway, L.A., and Sellers, W.R. (2006). Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6, 593–602.
Gibbons, D.L., Lin, W., Creighton, C.J., et al. (2009). Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23, 2140–2151.
Glazer, L., and Shilo, B.Z. (1991). The Drosophila FGF-R homolog is expressed in the embryonic tracheal system and appears to be required for directed tracheal cell extension. Genes Dev 5, 697–705.
Greenman, C., Stephens, P., Smith, R., et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158.
Greenman, C., Wooster, R., Futreal, P.A., Stratton, M.R., and Easton, D.F. (2006). Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 173, 2187–2198.
Hansen, H.H., Selawry, O.S., Simon, R., et al. (1976). Combination chemotherapy of advanced lung cancer: a randomized trial. Cancer 38, 2201–2207.
Hatley, M.E., Patrick, D.M., Garcia, M.R., et al. (2010). Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18, 282–293.
Hayashita, Y., Osada, H., Tatematsu, Y., et al. (2005). A polycistronic microRNA cluster, miR-17–92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65, 9628–9632.
Hayes, D.N., Monti, S., Parmigiani, G., et al. (2006). Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24, 5079–5090.
Hecht, S.S. (1999). Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91, 1194–1210.
Hecht, S.S. (2003). Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3, 733–744.
Heist, R.S., Mino-Kenudson, M., Sequist, L.V., et al. (2012). FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 7, 1775–1780.
Hingorani, S.R., Petricoin, E.F., Maitra, A., et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437–450.
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in human cancers. Science 253, 49–53.
Hu, Z., Chen, J., Tian, T., et al. (2008). Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 118, 2600–2608.
Imielinski, M., Berger, A.H., Hammerman, P.S., et al. (2012). Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120.
Johnson, S.M., Grosshans, H., Shingara, J., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120, 635–647.
Kaelin, W.G., Jr. (2005). The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5, 689–698.
Kajstura, J., Rota, M., Hall, S.R., et al. (2011). Evidence for human lung stem cells. N Engl J Med 364, 1795–1806.
Karnoub, A.E., Dash, A.B., Vo, A.P., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557–563.
Keshet, I., Lieman-Hurwitz, J., and Cedar, H. (1986). DNA methylation affects the formation of active chromatin. Cell 44, 535–543.
Kim, C.F., Jackson, E.L., Woolfenden, A.E., et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823–835.
Knudson, A.G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68, 820–823.
Kondo, M., Suzuki, H., Ueda, R., et al. (1995). Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 10, 1193–1198.
Kotton, D.N., and Fine, A. (2008). Lung stem cells. Cell Tissue Res 331, 145–156.
Kramer, S., Okabe, M., Hacohen, N., Krasnow, M.A., and Hiromi, Y. (1999). Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. Development 126, 2515–2525.
Kumar, M.S., Erkeland, S.J., Pester, R.E., et al. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105, 3903–3908.
Kumar, M.S., Hancock, D.C., Molina-Arcas, M., et al. (2012). The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655.
Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R., and Jacks, T. (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39, 673–677.
Kwak, E.L., Bang, Y.J., Camidge, D.R., et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363, 1693–1703.
Lane, A.A., and Chabner, B.A. (2009). Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27, 5459–5468.
Lockwood, W.W., Wilson, I.M., Coe, B.P., et al. (2012). Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One 7, e37775.
Lu, J., Getz, G., Miska, E.A., et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834–838.
Lynch, T.J., Bell, D.W., Sordella, R., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129–2139.
Mercer, T.R., Dinger, M.E., and Mattick, J.S. (2009). Long non-coding RNAs: insights into functions. Nat Rev Genet 10, 155–159.
Merlo, A., Herman, J.G., Mao, L., (1995). 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1, 686–692.
Metzger, R.J., Klein, O.D., Martin, G.R., and Krasnow, M.A. (2008). The branching programme of mouse lung development. Nature 453, 745–750.
Min, H., Danilenko, D.M., Scully, S.A., et al. (1998). Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev 12, 3156–3161.
Moody, T.W., Pert, C.B., Gazdar, A.F., Carney, D.N., and Minna, J.D. (1981). High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 214, 1246–1248.
Mucenski, M.L., Wert, S.E., Nation, J.M., et al. (2003). Beta-catenin is required for specification of proximal/distal cell fate during lung morphogenesis. J Biol Chem 278, 40231–40238.
Muller, P.A., and Vousden, K.H. (2013). p53 mutations in cancer. Nat Cell Biol 15, 2–8.
Murakami, M., Ichisaka, T., Maeda, M., et al. (2004). mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 24, 6710–6718.
Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., et al. (2010). Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42, 665–667.
Ogawa, O., Eccles, M.R., Szeto, J., et al. (1993). Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature 362, 749–751.
Osada, H., Tatematsu, Y., Yatabe, Y., Horio, Y., and Takahashi, T. (2005). ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 65, 10680–10685.
Paez, J.G., Janne, P.A., Lee, J.C., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500.
Pao, W., and Chmielecki, J. (2010). Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10, 760–774.
Pao, W., Miller, V.A., Politi, K.A., et al. (2005a). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73.
Pao, W., Wang, T.Y., Riely, G.J., et al. (2005b). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2, e17.
Parada, L.F., Tabin, C.J., Shih, C., and Weinberg, R.A. (1982). Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474–478.
Peifer, M., Fernandez-Cuesta, L., Sos, M.L., et al. (2012). Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44, 1104–1110.
Pepicelli, C.V., Lewis, P.M., and McMahon, A.P. (1998). Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr Biol 8, 1083–1086.
Perou, C.M., Sorlie, T., Eisen, M.B., et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747–752.
Pleasance, E.D., Stephens, P.J., O'Meara, S., et al. (2010). A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184–190.
Puyol, M., Martin, A., Dubus, P., et al. (2010). A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63–73.
Rawlins, E.L., and Hogan, B.L. (2006). Epithelial stem cells of the lung: privileged few or opportunities for many? Development 133, 2455–2465.
Reinhart, B.J., Slack, F.J., Basson, M., et al. (2000). The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901–906.
Rikova, K., Guo, A., Zeng, Q., et al. (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203.
Rivenson, A., Hoffmann, D., Prokopczyk, B., Amin, S., and Hecht, S.S. (1988). Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 48, 6912–6917.
Saito, R.A., Watabe, T., Horiguchi, K., et al. (2009). Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res 69, 2783–2791.
Sanchez-Cespedes, M., Parrella, P., Esteller, M., et al. (2002). Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62, 3659–3662.
Sandler, A., Gray, R., Perry, M.C., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355, 2542–2550.
Santos, E., Martin-Zanca, D., Reddy, E.P., et al. (1984). Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223, 661–664.
Schiller, J.H., Harrington, D., Belani, C.P., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346, 92–98.
Scholl, C., Frohling, S., Dunn, I.F., et al. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821–834.
Schuger, L., Varani, J., Mitra, R., Jr., and Gilbride, K. (1993). Retinoic acid stimulates mouse lung development by a mechanism involving epithelial-mesenchymal interaction and regulation of epidermal growth factor receptors. Dev Biol 159, 462–473.
Sekine, K., Ohuchi, H., Fujiwara, M., et al. (1999). Fgf10 is essential for limb and lung formation. Nat Genet 21, 138–141.
Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3, 75ra26.
Sharma, S.V., Lee, D.Y., Li, B., et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80.
Shaw, A.T., and Engelman, J.A. (2013). ALK in lung cancer: past, present, and future. J Clin Oncol 31, 1105–1111.
Singh, A., Greninger, P., Rhodes, D., et al. (2009). A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489–500.
Singh, A., and Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751.
Singh, S.K., Hawkins, C., Clarke, I.D., et al. (2004). Identification of human brain tumour initiating cells. Nature 432, 396–401.
Sjoblom, T., Jones, S., Wood, L.D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274.
Sorlie, T., Perou, C.M., Tibshirani, R., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869–10874.
Sos, M.L., Koker, M., Weir, B.A., et al. (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69, 3256–3261.
Stellman, S.D., Muscat, J.E., Hoffmann, D., and Wynder, E.L. (1997). Impact of filter cigarette smoking on lung cancer histology. Prev Med 26, 451–456.
Su, A.I., Welsh, J.B., Sapinoso, L.M., et al. (2001). Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61, 7388–7393.
Sun, S., Schiller, J.H., and Gazdar, A.F. (2007). Lung cancer in never smokers – a different disease. Nat Rev Cancer 7, 778–790.
Takamizawa, J., Konishi, H., Yanagisawa, K., et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64, 3753–3756.
Tan, D., Li, Q., Deeb, G., et al. (2003). Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 34, 597–604.
Thiery, J.P., and Sleeman, J.P. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7, 131–142.
Travis, W.D., Brambilla, E., Noguchi, M., et al. (2011). International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6, 244–285.
Travis, W.D., Lubin, J., Ries, L., and Devesa, S. (1996). United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 77, 2464–2470.
Varela, I., Tarpey, P., Raine, K., et al. (2011). Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542.
Warburton, D., Schwarz, M., Tefft, D., et al. (2000). The molecular basis of lung morphogenesis. Mech Dev 92, 55–81.
Weinstein, I.B. (2002). Cancer. Addiction to oncogenes – the Achilles heel of cancer. Science 297, 63–64.
Weinstein, M., Xu, X., Ohyama, K., and Deng, C.X. (1998). FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 125, 3615–3623.
Weir, B.A., Woo, M.S., Getz, G., et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893–898.
Wellner, U., Schubert, J., Burk, U.C., et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11, 1487–1495.
Wilk, R., Weizman, I., and Shilo, B.Z. (1996). trachealess encodes a bHLH-PAS protein that is an inducer of tracheal cell fates in Drosophila. Genes Dev 10, 93–102.
Winslow, M.M., Dayton, T.L., Verhaak, R.G., et al. (2011). Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473, 101–104.
Xu, X., Rock, J.R., Lu, Y., et al. (2012). Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc Natl Acad Sci USA 109, 4910–4915.
Yanaihara, N., Caplen, N., Bowman, E., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189–198.
Yang, A., Schweitzer, R., Sun, D., et al. (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714–718.
Yu, S.L., Chen, H.Y., Chang, G.C., et al. (2008). MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13, 48–57.
Yuan, B., Li, C., Kimura, S., et al. (2000). Inhibition of distal lung morphogenesis in Nkx2.1(–/–) embryos. Dev Dyn 217, 180–190.
Zhang, Z., Lee, J.C., Lin, L., et al. (2012). Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44, 852–860.
Zhao, X., Weir, B.A., LaFramboise, T., et al. (2005). Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65, 5561–5570.
Zhou, J., Su, P., Wang, L., et al. (2009). mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proc Natl Acad Sci USA 106, 7840–7845.
Zimmermann, G., Papke, B., Ismail, S., et al. (2013). Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497, 638–642.
Zoncu, R., Efeyan, A., and Sabatini, D.M. (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21–35.
